R Lipp
Overview
Explore the profile of R Lipp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt U, Lipp R, Drechsler M
Value Health
. 2016 May;
17(7):A629.
PMID: 27202233
No abstract available.
2.
Lindner C, Dierneder J, Pall G, Pirich C, Hoffmann M, Raderer M, et al.
Nuklearmedizin
. 2014 Nov;
54(3):125-30.
PMID: 25421138
There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently...
3.
Van Cutsem E, Li C, Nowara E, Aprile G, Moore M, Federowicz I, et al.
Br J Cancer
. 2014 Sep;
111(11):2067-75.
PMID: 25247318
Background: This phase II, open-label, randomised study evaluated whether patients with metastatic pancreatic cancer receiving erlotinib/gemcitabine derived survival benefits from increasing the erlotinib dose. Methods: After a 4-week run-in period...
4.
Strumberg D, Bergmann L, Graeven U, Hanauske A, Lipp R, Schuette J, et al.
Int J Clin Pharmacol Ther
. 2010 Jun;
48(7):470-2.
PMID: 20557848
No abstract available.
5.
Dunzinger A, Hafner F, Piswanger-Solkner J, Brodmann M, Lipp R
Nuklearmedizin
. 2008 Nov;
47(5):N70-2.
PMID: 18988339
No abstract available.
6.
Guthmann C, Lipp R, Wagner T, Kranz H
Eur J Pharm Biopharm
. 2008 Jan;
69(2):667-74.
PMID: 18226884
The drug substance SAG/ZK has a short biological half-life and because of its weakly basic nature a strong pH-dependent solubility was observed. The aim of this study was to develop...
7.
Guthmann C, Lipp R, Wagner T, Kranz H
Drug Dev Ind Pharm
. 2007 Apr;
33(3):341-9.
PMID: 17454067
SAG/ZK [3-(5-Chloro-2-[2-[(2R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl)uronium hydrogen sulfate], a potent candidate for the oral treatment of inflammatory diseases, demonstrated pH-dependent solubility. Drug release from conventional pellet formulations decreased with increasing pH values of the...
8.
Kranz H, Guthmann C, Wagner T, Lipp R, Reinhard J
Eur J Pharm Sci
. 2005 Jun;
26(1):47-53.
PMID: 15953712
ZK 811 752, a potent candidate for the treatment of autoimmune diseases, demonstrated pH-dependent solubility. The resulting release from conventional matrix tablets decreased with increasing pH-values of the dissolution medium....
9.
Schilling G, Lipp R, Hegewisch-Becker S, Hossfeld D
Oncology (Williston Park)
. 2000 Dec;
14(10 Suppl 9):38-40.
PMID: 11098490
This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with...
10.
Lipp R
Eur J Pharm Biopharm
. 1999 May;
47(2):133-8.
PMID: 10234537
Target of the study was to characterize crystals which had grown in steroid-containing matrix patches during short-term storage and to thereby establish a rationale for the inhibition of crystal formation...